| Expression pattern: |
UP |
| Associated gene: |
ATG2A |
| Associated microRNA: |
miR-376a |
| Biological function: |
Promotes laryngocarcinoma cisplatin resistance, colony formation, cell viability and in vivo tumor growth; inhibits apoptosis under cisplatin treatment. |
| Molecular mechanism: |
circPGAM1 acts as a ceRNA interacting with miR-376a and regulates downstream autophagy-related ATG2A/autophagy signaling to enhance cisplatin resistance. |
| Biological pathway or process: |
autophagy (promotes); drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Transfection; Colony Formation Assay; MTT; TUNEL; In Vivo Animal Model; Western Blot; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
circPGAM1 is higher in laryngocarcinoma tumors, high circPGAM1 expression is associated with shorter survival time, and higher tumor stages positively correlate with higher circPGAM1 expression. |
| Description: |
circPGAM1 is up-regulated in laryngocarcinoma tumors and promotes resistance to cisplatin. Mechanistically, it interacts with miR-376a as a ceRNA and regulates the downstream autophagy-related effector ATG2A/autophagy signaling. High circPGAM1 expression is associated with higher tumor stage and poorer survival. |
| Confidence score: |
0.6474 |